Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FNP 223 (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PROSPER
  • Sponsors Ferrer

Most Recent Events

  • 17 Jun 2025 According to a Ferrer media release, the company has received Fast Track designation from the US Food & Drug Administration (FDA) for FNP-223.
  • 17 Sep 2024 According to Ferrer media release , the company expected to include the participation of up to 220 participants and 46 clinical trial sites across the United States, the United Kingdom and 7 countries in the European Union and is currently recruiting in the United States, with additional countries expected to begin recruitment in the fourth quarter of 2024.
  • 17 Jun 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top